We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold STERIS (STE) Stock in Your Portfolio
Read MoreHide Full Article
STERIS plc (STE - Free Report) has been gaining from a robust performance across three of its reporting segments in the fourth quarter of fiscal 2022. A significant revenue contribution from acquisitions in the quarter buoys optimism. However, mounting operating expenses and stiff competition are concerning.
Over the past year, shares of this Zacks Rank #3 (Hold) company have gained 11.2% against the industry’s 15.4% rise. The S&P 500 fell 3.2% in the same period.
The renowned provider of infection prevention as well as other procedural products and services has a market capitalization of $21.82 billion. Its earnings for the fourth quarter of fiscal 2022 surpassed the Zacks Consensus Estimate by 2%.
Let’s delve deeper
Factors at Play
Impressive Q4 Results: STERIS exited fourth-quarter fiscal 2022 with better-than-expected earnings and revenues. Year-over-year growth in revenues and earnings appears promising. Robust performances across three of STERIS’ reporting segments contributed to top-line growth. A significant revenue contribution from acquisitions in the quarter buoys optimism. The expansion in the gross margin is an added advantage. The bullish guidance for fiscal 2023 is indicative that the growth momentum will continue.
STERIS' Infection Prevention and Sterilization Wing Grows Globally: With the acquisition of the U.K.-based outsourced sterilization services provider Synergy Health, STERIS has become the new global leader in infection prevention and sterilization. The company is currently providing improved healthcare services to medical device companies, pharma companies, hospitals and other healthcare facilities across the globe.
Image Source: Zacks Investment Research
The company continues to benefit from the acquisition of Synergy Health. The consolidation has boosted STERIS' presence in the international markets since its inception, as it combines STERIS’ strong presence in North America with Synergy's solid footprint across Europe, which is encouraging. It has also provided STERIS an opportunity to better serve the emerging markets of the Asia-Pacific and Latin America.
Overall Strong Solvency Position: STERIS exited fiscal 2022 with cash and cash equivalents of $348.3 million compared with $220.5 million at the end of fiscal 2021. Total debt (short and long term) at the end of 2022 was $2.95 billion compared with $1.65 billion a year ago. However, the company has no short-term debt on its balance sheet at the end of fiscal 2022. This is good news for its solvency level, at least during the pandemic when companies have been majorly facing manufacturing and supply halts.
Downsides
Mounting Expenses: In the fourth quarter of fiscal 2022, SG&A expenses climbed 105.2% year over year, whereas R&D expenses rose 49% year over year. These escalating operating expenses led to an 858-basis-points (bps) contraction in the operating margin, building pressure on the bottom line.
Competitive Landscape: STERIS competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach, and a number of small companies with limited product offerings and operations in one or a few countries. In the Healthcare segment, STERIS’ notable competitors are 3M, Belimed, Ecolab, Getinge, Go Jo, Johnson & Johnson, Kimberly-Clark, Skytron and Stryker.
Estimate Trend
STERIS has been witnessing a positive estimate revision trend for fiscal 2023. In the past 90 days, the Zacks Consensus Estimate for STERIS’ earnings has moved 0.1% north to $8.79.
The Zacks Consensus Estimate for fiscal 2023 revenues is pegged at $4.89 billion, suggesting 6.7% growth from the fiscal 2022 reported number.
Key Picks
A few better-ranked stocks in the broader medical space are UnitedHealth Group Incorporated (UNH - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Alkermes plc (ALKS - Free Report) .
UnitedHealth, with a Zacks Rank #2 (Buy), reported first-quarter 2022 earnings per share (EPS) of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 14.2%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%.
Medpace reported first-quarter 2022 adjusted EPS of $1.69, which surpassed the Zacks Consensus Estimate by 34.1%. Revenues of $330.9 million outpaced the Zacks Consensus Estimate by 1.1%. It currently has a Zacks Rank #2.
Medpace has a historical growth rate of 27.3%. MEDP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.1%.
Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which surpassed the Zacks Consensus Estimate of a penny. Revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently sports a Zacks Rank #1.
Alkermes has an estimated long-term growth rate of 25.1%. ALKS’ earnings surpassed estimates in the trailing four quarters, the average surprise being 350.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Hold STERIS (STE) Stock in Your Portfolio
STERIS plc (STE - Free Report) has been gaining from a robust performance across three of its reporting segments in the fourth quarter of fiscal 2022. A significant revenue contribution from acquisitions in the quarter buoys optimism. However, mounting operating expenses and stiff competition are concerning.
Over the past year, shares of this Zacks Rank #3 (Hold) company have gained 11.2% against the industry’s 15.4% rise. The S&P 500 fell 3.2% in the same period.
The renowned provider of infection prevention as well as other procedural products and services has a market capitalization of $21.82 billion. Its earnings for the fourth quarter of fiscal 2022 surpassed the Zacks Consensus Estimate by 2%.
Let’s delve deeper
Factors at Play
Impressive Q4 Results: STERIS exited fourth-quarter fiscal 2022 with better-than-expected earnings and revenues. Year-over-year growth in revenues and earnings appears promising. Robust performances across three of STERIS’ reporting segments contributed to top-line growth. A significant revenue contribution from acquisitions in the quarter buoys optimism. The expansion in the gross margin is an added advantage. The bullish guidance for fiscal 2023 is indicative that the growth momentum will continue.
STERIS' Infection Prevention and Sterilization Wing Grows Globally: With the acquisition of the U.K.-based outsourced sterilization services provider Synergy Health, STERIS has become the new global leader in infection prevention and sterilization. The company is currently providing improved healthcare services to medical device companies, pharma companies, hospitals and other healthcare facilities across the globe.
The company continues to benefit from the acquisition of Synergy Health. The consolidation has boosted STERIS' presence in the international markets since its inception, as it combines STERIS’ strong presence in North America with Synergy's solid footprint across Europe, which is encouraging. It has also provided STERIS an opportunity to better serve the emerging markets of the Asia-Pacific and Latin America.
Overall Strong Solvency Position: STERIS exited fiscal 2022 with cash and cash equivalents of $348.3 million compared with $220.5 million at the end of fiscal 2021. Total debt (short and long term) at the end of 2022 was $2.95 billion compared with $1.65 billion a year ago. However, the company has no short-term debt on its balance sheet at the end of fiscal 2022. This is good news for its solvency level, at least during the pandemic when companies have been majorly facing manufacturing and supply halts.
Downsides
Mounting Expenses: In the fourth quarter of fiscal 2022, SG&A expenses climbed 105.2% year over year, whereas R&D expenses rose 49% year over year. These escalating operating expenses led to an 858-basis-points (bps) contraction in the operating margin, building pressure on the bottom line.
Competitive Landscape: STERIS competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach, and a number of small companies with limited product offerings and operations in one or a few countries. In the Healthcare segment, STERIS’ notable competitors are 3M, Belimed, Ecolab, Getinge, Go Jo, Johnson & Johnson, Kimberly-Clark, Skytron and Stryker.
Estimate Trend
STERIS has been witnessing a positive estimate revision trend for fiscal 2023. In the past 90 days, the Zacks Consensus Estimate for STERIS’ earnings has moved 0.1% north to $8.79.
The Zacks Consensus Estimate for fiscal 2023 revenues is pegged at $4.89 billion, suggesting 6.7% growth from the fiscal 2022 reported number.
Key Picks
A few better-ranked stocks in the broader medical space are UnitedHealth Group Incorporated (UNH - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Alkermes plc (ALKS - Free Report) .
UnitedHealth, with a Zacks Rank #2 (Buy), reported first-quarter 2022 earnings per share (EPS) of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 14.2%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%.
Medpace reported first-quarter 2022 adjusted EPS of $1.69, which surpassed the Zacks Consensus Estimate by 34.1%. Revenues of $330.9 million outpaced the Zacks Consensus Estimate by 1.1%. It currently has a Zacks Rank #2.
Medpace has a historical growth rate of 27.3%. MEDP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.1%.
Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which surpassed the Zacks Consensus Estimate of a penny. Revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently sports a Zacks Rank #1.
Alkermes has an estimated long-term growth rate of 25.1%. ALKS’ earnings surpassed estimates in the trailing four quarters, the average surprise being 350.5%.